Follow The Money, An Interactive Biotech Financing Map
In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.
You may also be interested in...
Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.
While major biotech indices went south in 2018, VC enthusiasm for biotech remained bullish. Biotech companies raised a record $22.83bn in 2018.
The Suzhou-based drug developer brings in new cash as US venture deals take a holiday. Also, France's Genfit may go public in the US, Taiwan Liposome launches its IPO, and Bioblast's strategic review ends in a reverse merger.